Raymond James Financial
RPRX icon

Raymond James Financial’s Royalty Pharma RPRX Stock Holding History

Raymond James Financial’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.7M Buy
1,599,881
+75,863
+5% +$3.95M 0.02% 622
2026
Q1 		$72.7M Buy
1,524,018
+56,419
+4% +$2.47M 0.02% 652
2025
Q4 		$56.8M Buy
1,467,599
+16,896
+1% +$644K 0.02% 761
2025
Q3 		$51.2M Buy
1,450,703
+326,615
+29% +$11.8M 0.02% 795
2025
Q2 		$40.5M Buy
1,124,088
+37,099
+3% +$1.23M 0.01% 887
2025
Q1 		$33.8M Buy
1,086,989
+303,356
+39% +$9.62M 0.01% 949
2024
Q4 		$20M Buy
+783,633
New +$20.8M 0.01% 1310

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's RPRX Position: Q2 2026 in Review

Raymond James Financial increased its Royalty Pharma (RPRX) stake by 5% in Q2 2026, buying an estimated $3.95M and bringing the position to 1,599,881 shares worth $89.7M. The position accounts for 0.02% of the portfolio, ranked #622.

Raymond James Financial first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Raymond James Financial held 1,599,881 shares of Royalty Pharma worth $89.7M as of Q2 2026.
  • Raymond James Financial bought 75,863 Royalty Pharma shares in Q2 2026, an estimated $3.95M.
  • Royalty Pharma made up 0.02% of Raymond James Financial's portfolio in Q2 2026, its #622 holding.
  • Raymond James Financial first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.